Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.64 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | KIT | P10721 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | AXL | P30530 | 6/20 | 0.64 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.63 |
| ▸ | MERTK | Q12866 | 2/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | MST1R | Q04912 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721300 | 0.91 | AXL (0.62) | METCYP3A4CYP2C9RIPK3RIPK1 | |
| SCHEMBL16817179 | 0.90 | MET (0.51) | METCYP3A4CYP2C9RIPK3RIPK1 | |
| SCHEMBL724084 | 0.88 | MET (0.67) | METCYP3A4CYP2C9RIPK3RIPK1 | |
| SCHEMBL723382 | 0.86 | MET (0.58) | METCYP3A4CYP2C9RIPK3RIPK1 | |
| SCHEMBL723448 | 0.86 | MET (0.69) | METLCKKITKDRFLT3 | |
| SCHEMBL16638611 | 0.84 | MET (0.47) | METCYP3A4CYP2C9RIPK3RIPK1 | |
| SCHEMBL16817164 | 0.82 | MET (0.48) | METCYP3A4CYP2C9RIPK3RIPK1 | |
| SCHEMBL23146997 | 0.82 | MET (0.71) | METCYP3A4CYP2C9RIPK3RIPK1 | |
| SCHEMBL16817165 | 0.82 | MET (0.54) | METLCKKITKDRFLT3 | |
| SCHEMBL16817176 | 0.80 | AXL (0.47) | METCYP3A4CYP2C9RIPK3RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | SYK, FCGRT, SSB | MET 1482/4885CYP3A4 2796/4885CYP2C9 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.